Welcome to our dedicated page for Donaldson Company news (Ticker: $DCI), a resource for investors and traders seeking the latest updates and insights on Donaldson Company stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Donaldson Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Donaldson Company's position in the market.
Donaldson celebrated its 2024 patent recipients and Inventor Award winners, recognizing 100 individuals for their contributions to filtration technology. The company, with over 4,373 active patents and 190 new patents awarded last fiscal year, continues its legacy of innovation. Key awards include the Technology Achievement Award for the Hydraulic Deaeration team, Technology Champion Award to Kristoff Decoster, Emerging Innovator Award to Michael Dzuricky, Richard M. Negri Manufacturing Excellence Award to Steve Dodd, and Frank A. Donaldson Award to Ben Nelson. Donaldson remains a global leader in filtration solutions, serving diverse industries through its Mobile Solutions, Industrial Solutions, and Life Sciences segments.
Donaldson and PolyPeptide have partnered to enhance sustainability in peptide manufacturing by developing a solvent recovery system for peptide purification. Leveraging Donaldson's filtration expertise and PolyPeptide's peptide synthesis skill, the technology reclaims and purifies acetonitrile, significantly reducing solvent consumption and waste. The system, piloted at PolyPeptide's Torrance site, reduces environmental impact by reclaiming solvents typically incinerated post-use. This collaboration aligns with both companies' commitment to sustainable manufacturing and green chemistry principles.
Donaldson Company, Inc. (NYSE: DCI) is developing an integrated upstream and downstream platform for viral vector manufacturing, focusing on lentivirus (LV) production to improve recoveries and reduce manufacturing complexity. The platform aims to accelerate process development timelines and lower costs in the production of cell and gene therapies. Univercells Technologies and Isolere Bio are collaborating on this initiative, with Isolere's IsoTag LV affinity purification reagent offering high functional recoveries and purity, while Univercells Technologies' scale-X bioreactor demonstrates high yields of LV in perfusion mode. The project is a strategic move by Donaldson to enhance its presence in the bioprocessing space through innovative acquisitions.
Donaldson Company, Inc. (NYSE: DCI) will present at the Oppenheimer 19th Annual Industrial Growth Conference on May 6, 2024. The CFO, Scott Robinson, will represent the company at 12:00 p.m. ET. The presentation can be accessed via live webcast on the company's Investor Relations website. Donaldson is a technology-led filtration products provider, serving various industries globally.
Donaldson Company, Inc. (NYSE: DCI) will webcast its third-quarter 2024 earnings conference call on June 4, 2024, at 9:00 a.m. CT. The webcast replay will be available on the company's Investor Relations website. Donaldson, founded in 1915, is a global leader in filtration products serving various industries.
Donaldson Company, a leading provider of filtration products, announced acquiring a 49% stake in Medica S.p.A., a leader in hollow fiber membrane filtration technology. Medica, generating €80 million in revenue in 2023, specializes in blood purification and water purification products. The acquisition is pending the outcome of a tender offer and is expected to be completed by Q3 2024.